Genzyme Corp Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GENZYME CORP, and when can generic versions of GENZYME CORP drugs launch?
GENZYME CORP has three approved drugs.
There are five US patents protecting GENZYME CORP drugs.
There are one hundred and seventy-six patent family members on GENZYME CORP drugs in fifty countries and twenty-three supplementary protection certificates in sixteen countries.
Summary for Genzyme Corp
| International Patents: | 176 |
| US Patents: | 5 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
| Drug Master File Entries: | 9 |
| Patent Litigation for Genzyme Corp: | See patent lawsuits for Genzyme Corp |
Drugs and US Patents for Genzyme Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-001 | Apr 6, 2011 | RX | Yes | No | 8,067,427 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Genzyme Corp | FLUDARA | fludarabine phosphate | INJECTABLE;INJECTION | 020038-001 | Apr 18, 1991 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Genzyme Corp | CERDELGA | eliglustat tartrate | CAPSULE;ORAL | 205494-001 | Aug 19, 2014 | AB | RX | Yes | Yes | 7,196,205 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-002 | Apr 6, 2011 | RX | Yes | Yes | 8,067,427 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Genzyme Corp | CERDELGA | eliglustat tartrate | CAPSULE;ORAL | 205494-001 | Aug 19, 2014 | AB | RX | Yes | Yes | 10,888,544 | ⤷ Sign Up | ⤷ Sign Up | |||
| Genzyme Corp | CERDELGA | eliglustat tartrate | CAPSULE;ORAL | 205494-001 | Aug 19, 2014 | AB | RX | Yes | Yes | 11,458,119 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |
| Genzyme Corp | CERDELGA | eliglustat tartrate | CAPSULE;ORAL | 205494-001 | Aug 19, 2014 | AB | RX | Yes | Yes | 10,888,547 | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Genzyme Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-002 | Apr 6, 2011 | RE42353 | ⤷ Sign Up |
| Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-001 | Apr 6, 2011 | 7,173,038 | ⤷ Sign Up |
| Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-001 | Apr 6, 2011 | 8,642,608 | ⤷ Sign Up |
| Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-001 | Apr 6, 2011 | RE42353 | ⤷ Sign Up |
| Genzyme Corp | CERDELGA | eliglustat tartrate | CAPSULE;ORAL | 205494-001 | Aug 19, 2014 | 6,916,802 | ⤷ Sign Up |
| Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-002 | Apr 6, 2011 | 8,642,608 | ⤷ Sign Up |
| Genzyme Corp | FLUDARA | fludarabine phosphate | INJECTABLE;INJECTION | 020038-001 | Apr 18, 1991 | 4,357,324*PED | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GENZYME CORP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tartrate Capsules | 84mg | ➤ Subscribe | 2018-08-20 |
International Patents for Genzyme Corp Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 201592195 | ⤷ Sign Up |
| Slovenia | 3133070 | ⤷ Sign Up |
| Japan | 2005255686 | ⤷ Sign Up |
| Cyprus | 1113402 | ⤷ Sign Up |
| Brazil | PI0211379 | ⤷ Sign Up |
| European Patent Office | 2067775 | ⤷ Sign Up |
| Ukraine | 81732 | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Genzyme Corp Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1409467 | 92717 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: ELIGLUSTAT, EVENTUELLEMENT SOUS LA FORME D UN SEL PHYSIOLOGIQUEMENT ACCEPTABLE. FIRST REGISTRATION: 20150121 |
| 1409467 | C20150027 00161 | Estonia | ⤷ Sign Up | PRODUCT NAME: ELIGLUSTAAT;REG NO/DATE: EU/1/14/974 21.01.2015 |
| 1244647 | SPC/GB12/036 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: VANDETANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/749/001 20120217; UK EU/1/11/749/002 20120217 |
| 1409467 | 132016000023075 | Italy | ⤷ Sign Up | PRODUCT NAME: ELIGLUSTAT, OPZIONALMENTE NELLA FORMA DI UN SALE FARMACOLOGICAMENTE ACCETTABILE(CERDELGA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/974, 20150119 |
| 1409467 | 1590029-3 | Sweden | ⤷ Sign Up | PRODUCT NAME: ELIGLUSTAT, VALFRITT I FORM AV ETT FYSIOLOGISKT GODTAGBART SALT; REG. NO/DATE: EU/1/14/974 20150121 |
| 1409467 | C300738 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ELIGLUSTAT, OF FYSIOLOGISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/974 20150119 |
| 1244647 | C 2012 023 | Romania | ⤷ Sign Up | PRODUCT NAME: VANDETANIB SAU O SARE ACCEPTABILA FARMACEUTIC AACESTUIA; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/749/001, RO EU/1/11/749/002; DATE OF NATIONAL AUTHORISATION: 20120217; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/749/001, EMEA EU/1/11/749/002; DATE OF FIRST AUTHORISATION IN EEA: 20120217 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
